Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label cAd3 Marburg vaccine study in adults during a Marburg outbreak
PACTR202412708603314Phase 2Recruiting
- Sponsor
- Rwanda Biomedical Centre
- Start
- Oct 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in Marburg virus disease (MVD), sponsored by Rwanda Biomedical Centre. Primary endpoints: Serious adverse events, Solicited adverse events and 4 more. Started Oct 2024; status: recruiting.
02
Conditions
Marburg virus disease (MVD)
Beyond the preview
Go deeper on PACTR202412708603314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202412708603314.